Price Alert

MAIA Biotechnology Inc. (MAIA)

AMEX: MAIA · Real-Time Price · USD

1.59

0.01 (0.63%)

At close: Aug 18, 2025, 3:59 PM

1.61

1.26%

After-hours: Aug 18, 2025, 07:12 PM EDT

0.63% (1D)

Bid	1.52
Market Cap	52.46M
Revenue (ttm)	n/a
Net Income (ttm)	-19.7M
EPS (ttm)	-0.54
PE Ratio (ttm)	-2.94
Forward PE	-2.19
Analyst	n/a

Ask	1.62
Volume	102,000
Avg. Volume (20D)	417,109
Open	1.59
Previous Close	1.58
Day's Range	1.56 - 1.62
52-Week Range	1.40 - 3.74
Beta	0.03

About MAIA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MAIA

Website n/a

Full Company Profile

Why Price Moved

1 month ago

+9.24%

MAIA Biotechnology shares are trading higher after... Unlock content with Pro Subscription

1 month ago

+6.67%

MAIA Biotechnology shares are trading higher. The company announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies 2025 Congress.

News

3 weeks ago · businesswire.com

MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer.

1 month ago · businesswire.com

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy.

1 month ago · businesswire.com

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer.

1 month ago · https://www.marketscreener.com

MAIA Biotechnology, Inc. announced that it expects to receive $0.587904 million in funding from Prevail Partners

MAIA Biotechnology, Inc entered into a stock purchase agreement at maximum of 337,876 shares at a price $1.74 per share for gross proceeds $5,87,904.24 on June 26, 2025. The transaction included parti...